FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer (FASTR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01439542
Recruitment Status : Terminated (Higher then expected Gr3 GU/GI toxicity)
First Posted : September 23, 2011
Last Update Posted : July 24, 2014
Information provided by (Responsible Party):
George Rodrigues, Lawson Health Research Institute

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Estimated Primary Completion Date : December 2021
  Study Completion Date : No date given